<DOC>
	<DOCNO>NCT02508090</DOCNO>
	<brief_summary>Genotype 1 CHC participant Study SPC3649-207 null response prior pegylated-interferon alpha plus ribavirin enrol 36-month extension study , design evaluate long-term safety efficacy 12 week miravirsen monotherapy . Due observational nature study , miravirsen dose investigational product .</brief_summary>
	<brief_title>Long-Term Extension Study Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C ( CHC ) Who Have Not Responded Pegylated-Interferon Alpha Plus Ribavirin</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Participants Study SPC3649207 , include complete study discontinue terminate study early reason , opt receive approved therapy treatment hepatitis C virus ( HCV ) infection Participants receive investigational drug therapy discontinuation , termination , completion Study SPC3649207</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>